![](/img/client_headers/GoodwinProcter/1-BigMoleculeWatch-2016-onwards.jpg)
Teva Pharmaceutical Industries Ltd., Celltrion, Inc. and Celltrion Healthcare announced that the companies have entered into an exclusive partnership to commercialize two of Celltrion’s biosimilar candidates: CT-P10, a proposed mAb biosimilar to Rituxan (rituximab), and CT-P6, a proposed mAb biosimilar to Herceptin (trastuzumab).
Stay tuned to the Big Molecule Watch for further developments.